Sales & Marketing News | pharmaphorum

News

FDA accelerated approval path needs improvement, says ICER

The FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.

News

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.

News

Novo Nordisk partners OpenAI on R&D "transformation"

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

News

Travere claims first FDA OK in rare kidney disease FSGS

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

FDA accelerated approval path needs improvement, says ICER

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

Daiichi exits OTC, with $1.55bn unit sale to Suntory

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

Novo Nordisk partners OpenAI on R&D "transformation"

Travere claims first FDA OK in rare kidney disease FSGS

UK Knowledge Quarter welcomes Boehringer Ingelheim AI accele...

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks